Global Lung Cancer Diagnosis and Therapeutics Market Research and Forecast 2018-2023

Global lung cancer diagnostics and therapeutics market size, share, market trends, research and analysis report by therapy (chemotherapy, targeted, immunotherapy, radiation) by diagnosis (CT scan, X-rays, lung cancer screening, needle biopsy, bronchoscopy, sputum cytology) forecast 2018-2023

According to the OMR analysis, the global lung cancer diagnosis and therapeutics market is expected to grow significantly during forecast period due to rising prevalence of cancer disease, globally. The global lung cancer diagnosis and therapeutics market is segmented on the basis of type, therapy, diagnosis and end user. The report provides detailed and insightful chapters on market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market share analysis, competitive landscape, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

Full report of global lung cancer diagnosis and therapeutics market is available at https://www.omrglobal.com/industry-reports/lung-cancer-diagnostics-market/

Over the last decades, an unprecedented change in human lifestyles has been observed. These lifestyles brought some major health challenges that lead to adverse effects on individuals. Smoking and tobacco are such major habits which are increasing the prevalence of various respiratory diseases and cancer. Smoking is the principal cause of lung cancer. According to World Cancer Research Fund International, smoking is responsible for around 85% of all types of this cancer. Men who smoke are 23 times more likely to develop lung cancer. More than 1.8 million of new cases were diagnosed in 2012. An estimated 1.6 million deaths reported in 2012 which is extensively high when compared to 2002 deaths due to lung cancer. Approximately, 1.18 million deaths were recorded in 2002 which shows an increase of 34% over these years. About 58 percent of lung cancer cases accounted from less developed countries. Europe and North America recorded the maximum number of lung cancer incidences while Africa and, Latin America and Caribbean hold the lowest incidence of lung cancer. While, Hungary had the highest rate of lung cancer, followed by Serbia and Democratic People's Republic of Korea. Additionally, as per American Lung
Association, geriatric population has the maximum probability to be detected with lung cancer. 83 % of lung cancer patients were 60 years of age or older in the year 2013. In Europe, more than 410,000 new cases of lung cancer were diagnosed in 2012. Lung cancer is the third most common cancer in the UK during 2013-14. It accounts for 13% of all new cases. The region recorded approx. 46,400 new cases of lung cancer in 2014 and 130 cases diagnosed every day. Over the last decade, 4 percent increase in lung cancer incidence rates recorded. The key players in the lung cancer diagnosis and therapeutics market include AstraZeneca plc, Eli lilly and Sanofi-Aventis, Arqule Inc, Daiichi Sankyo co. Ltd, Celgene, Merck, Pfizer, Ventana, Roche, Genentech, Glaxosmith, Boehringer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, AbbVie, Pharmacyclics.

Global lung cancer diagnosis and therapeutics market by region is segmented into North America, Europe, Asia pacific and rest of the world in which Asia pacific region is growing at a significant rate due to rising incidence and prevalence of cancer. North America is dominating this market as the major market leaders are situated in this region. North America holds the significant market share of the global lung cancer diagnosis and therapeutics market, followed by Europe.

The report covers:
Comprehensive research methodology of global lung cancer diagnostics and therapeutics market
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global lung cancer diagnostics and therapeutics market
Insights about market determinants which are stimulating the global lung cancer diagnostics and therapeutics market
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

For related reports please visit https://www.omrglobal.com/reports-category/biotechnology/

For more update follow LinkedIn https://www.linkedin.com/company/omr-global-research/

About Orion Market Research

Orion Market Research (OMR) a research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company aims to provide business insights for decision making to the global clients and offers quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Contact us

Orion Market Research Pvt. Ltd.
Anurag Tiwari
Email: info@omrglobal.com, support@omrglobal.com
India: +91-780-304-0404, +91-917-982-8694
Global:+1-646-755-7667
Indore-India-452010
Web: www.omrglobal.com

This release was published on openPR.